The German phase III clinical trial FIRE-3 reports that first-line cetuximab (Erbitux?, Merck KGaA) plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) offers a roughly four-month survival advantage for patients with metastatic colorectal cancer, compared with bevacizumab (Avastin?, Genentech/Roche) plus FOLFIRI. The targeted drugs cetuximab and bevacizumab, both in combination with chemotherapy, are approved and commonly used as initial therapy but, until this study, it has been unclear which approach is better for patients with non-mutated forms of the KRAS gene.

These findings, presented at the 49th Annual Meeting of the American Society of Clinical Oncology(ASCO), being held May 31 – June 4, 2013, suggest that first-line treatment with cetuximab in combination with FOLFIRI is superior, whereas bevacizumab could be reserved for second-line therapy.

?This degree of survival benefit was equivalent to the survival benefit seen in clinical trials that led to the approval of cetuximab and bevacizumab in this setting,? said Volker Heinemann, MD, PhD, (Photo) a professor of medical oncology at the University of Munichin Munich, Germany. ?We suspected that cetuximab would produce a better response, but we didn?t know this would translate into better survival.?


First-line cetuximab plus FOLFIRI leads to an approximately four-month survival gain compared to bevacizumab plus FOLFIRI.


In the study, 592 patients with non-mutated (wild-type) KRAS metastatic colorectal cancer were randomly assigned to first-line therapy with FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab.

Overall response rate favored FOLFIRI plus cetuximab, but reached the level of significance only in assessable patients. These patients (n=526) were required to have at least one imaging procedure after baseline. The median time to disease progression (progression-free survival) was nearly identical in the two arms (10.0 vs. 10.3 months), but the overall survival was markedly longer in the cetuximab arm (28.7 months) compared to the bevacizumab arm (25.0 months).

While FOLFIRI is standard chemotherapy for patients with metastatic colorectal cancer in Germany, in the United States, patients more commonly receive FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin).

Both chemotherapy regimens have been found to be very effective in combination with cetuximab and bevacizumab in prior studies. A head-to-head comparison study of bevacizumab plus FOLFOX vs. cetuximab plus FOLFOX is ongoing.

?Patients confronting advanced colorectal cancer and their doctors are striving to extend lives. In the FIRE-3 trial initial therapy with FOLFIRI and cetuximab helped achieve that goal,? said Richard M. Goldberg, MD, a gastrointestinal cancers expert and ASCO spokesperson. ?The study prescribed the initial chemotherapy and in both groups tumors eventually grew at a similar pace. More research is needed to explain the overall survival benefit observed in this study, given the lack of improvement in progression free survival.?

Cetuximab is a monoclonal antibody (MAb) that specifically targets the epidermal growth factor receptor (EGFR) with a high affinity and competitively inhibits endogenous ligand binding, blocking tumor growth. The agent is currently approved only for patients with no KRAS gene mutations in their tumors, which account for about 60% of all colorectal cancer cases. Prior studies have shown that mutations in KRAS undermine the activity of anti-EGFR treatments. Bevacizumab targets a protein called VEGF, which is involved in the growth of tumor blood vessels. It appears that KRAS mutation status does not affect responsiveness to bevacizumab.

Researchers are also working on identifying molecular markers that predict response to bevacizumab vs. cetuximab.

Clinical trials:
NCT00433927 – 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

For more information:
Abstract #LBA3506: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
Oral Abstract Session: GI (Colorectal) Cancer Study
Study author: Volker Heinemann, MD, PhD, University of Munich, Munich, Germany
Date: Saturday, June 1, 2013, 4:45 ? 5:00 PM CDT
Location: Room: E Hall D1

Photo: Volker Heinemann, MD, PhD. Photo Courtesy: ? ASCO/Brian Powers 2013.

Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement